DSG3-CAART

Phase 2Biologic

CCabaletta Bio

DSG3-CAART is one of 8 biologic programs targeting Pemphigus Vulgaris. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Pemphigus VulgarisRecruiting

Pemphigus VulgarisPhase 2

Recruiting

Competition

Competitive Landscape

7 competitors in Pemphigus Vulgaris

#DrugCompanyPhaseTrials

Cellcept

Roche

Approved

2 2

Orencia

Bristol-Myers Squibb

Approved

1 3

Decadron

AAspen Global Incorporated

CABA-201

1 5

Rituxan

Pfizer

Phase 1

1 6

Decadron

QQuince Therapeutics S.p.A.

DSG3-CAART

1 8

Medication

NNYU Langone Health

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2029

Phase 1/2Recruiting

Pemphigus Vulgaris

NCT04422912

Clinical

Trials by Indication[1]

Pemphigus Vulgaris1 trial

A Phase 1/2, Open-label, Safety and Dosing Study of Autologous CART Cells (Desmoglein 3 Chimeric Autoantibody Receptor T Cells [DSG3-CAART] or CD19-specific Chimeric Antigen Receptor T Cells [CABA-201]) in Subjects With Active, Pemphigus Vulgaris (RESET-PV)

Recruiting·CCabaletta Bio·Phase 1/2·NCT04422912·40 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for DSG3-CAART. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — DSG3-CAART compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for DSG3-CAART. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Cabaletta Bio company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 2[1]
Company: CCabaletta Bio

DSG3-CAART

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2029

Trials by Indication[1]

Pemphigus Vulgaris1 trial

References

Drug Info

Quick Facts

Related News